Exscientia has initiated the EXCYTE-2 observational clinical study in acute myeloid leukaemia (AML). The study aims to explore the correlation between ex vivo drug response (EVDR) measured in primary blood or bone marrow samples using Exscientia's precision medicine platform and actual patient clinical responses.
The research will focus on first-line AML patients, with an option to expand to second-line patients, addressing areas with high unmet medical needs and low survival rates. The study will utilise biobanked tissue samples and clinical patient data, with Exscientia's cloud-based AI being employed by partner laboratories for remote sample analysis. The evaluation will also include the activity of Exscientia's LSD1 inhibitor, '539, potentially supporting the development of the inhibitor for future clinical trials.
The EXCYTE-2 study builds on previous precision medicine-focused studies like EXALT-1 and EXCYTE-1. EXALT-1 was an interventional trial leveraging deep learning to guide treatment selection for late-stage haematological cancers. EXCYTE-2, focusing on earlier-stage patient populations, utilises advancements in Exscientia's AI-driven precision medicine platform.
The study aims to establish AI-led ex vivo drug testing in human tissue samples as a comprehensive strategy for preclinical testing, potentially influencing clinical practice for the benefit of AML patients, according to Dr. Nikolaus Krall, EVP of Precision Medicine at Exscientia.
Click here to read the original news story.